hotspot -WSS

hotspot

author：comprehensive 2025-09-29 01:36:08 - browse：9838

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： 'Ancient DNA,' 23andMe reveal African American ancestries

hotspot

WSS

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

CDC's new outbreak response network to include Northeastern

What the cancer research community can learn from the Covid response

Verily hires former Apple Health leader as chief scientific officer

A cyberattack has disrupted hospitals and health care in several states

Thermo Fisher plant for manufacturing gene therapies to expand

leisure time

hotspot

leisure time

Tori Bowie and the unacceptable rates of Black maternal death

Microbiome research is starting to find links to chronic diseases

Continuity nursing helped my family in our darkest PICU moments

CommonSpirit Health keeps growing, even as it loses money

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Hearing on Medicare drug price negotiation gets unusually heated

DIEP, the 'gold standard' of breast reconstruction, is under threat

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Affirmative action in medical school literally saved lives

FDA panel to weigh approval of NurOwn, controversial ALS drug

entertainment

Senate HELP committee spars over health care workforce policies

Biotech stock slump in 2023: awaiting the turnaround

Attacks on the drug industry will lead to fewer breakthroughs

Thermo Fisher plant for manufacturing gene therapies to expand

Ukraine and a new approach to mental health in war

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

hotspot

knowledge

explore

hotspot